The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In 2024, new medicines changed how we think about healthy weight loss—but psychological factors remain just as important as ...

Both drugs are part of the GLP-1 class that has shown unprecedented results for helping people shed weight by decreasing ... produce customized versions of prescription medications — for ...

Drugs like Ozempic and Wegovy have skyrocketed in popularity over the past few years. To capitalize on that demand, telehealth companies started offering compounded versions of those drugs.

According to the Centers for Disease Control and Prevention (CDC), 2 in 5 people in the United States have obesity. The obesity rate was 30.5% from 1999 to 2000. From 2017 to 2020, it increased to ...

and type 2 diabetes within 15 days of an initial prescription for a GLP-1 weight-loss drug between 2020 and 2024. In addition to obesity-related conditions, some patients are being prescribed the ...

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...